UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2009
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| | | | | |
| Massachusetts | | 001-33284 | | 04-0562086 |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
160 Second Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices, Including Zip Code)
(617) 492-5554
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 2.02. Results of Operations and Financial Condition.
On May 11, 2009, Molecular Insight Pharmaceuticals, Inc. issued a press release announcing the financial results of the Company for the three months ended March 31, 2009. A copy of the press release is furnished with this report as Exhibit 99.1 to this Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
| | (d) | | Exhibits. The following exhibit is furnished pursuant to Item 2.02: |
| | 99.1 | | Press Release of Molecular Insight Pharmaceuticals, Inc. dated May 11, 2009. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized, on the 11 th day of May, 2009.
| | | | | |
| | MOLECULAR INSIGHT PHARMACEUTICALS, INC.
| |
| | By: | /s/ John W. Babich, Ph.D. | |
| | | Name: | John W. Babich, Ph.D. | |
| | | Title: | President and Chief Executive Officer | |
3
Exhibit Index to Current Report on Form 8-K
| | | |
| Exhibit | | |
| Number | | |
| 99.1 | | Press Release of Molecular Insight Pharmaceuticals, Inc. dated May 11, 2009 |
